Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced gly...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2015-01-01
|
| Series: | Clinical Medicine Insights: Endocrinology and Diabetes |
| Online Access: | https://doi.org/10.4137/CMED.S31526 |
| _version_ | 1818854843648835584 |
|---|---|
| author | Curtis Triplitt Susan Cornell |
| author_facet | Curtis Triplitt Susan Cornell |
| author_sort | Curtis Triplitt |
| collection | DOAJ |
| description | Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated with a low risk of hypoglycemia when used either as monotherapy or with other agents not typically associated with increased risk of hypoglycemia. Collaborative, multidisciplinary teams are best suited to provide care to patients with diabetes, and clinical pharmacists can enhance the care provided by these teams. This review aims to provide insight into the mode of action, pharmacology, potential drug–drug interactions, clinical benefits, and safety considerations associated with use of the SGLT2 inhibitor canagliflozin in patients with T2DM and to provide information to enhance clinical pharmacists' understanding of canagliflozin. |
| first_indexed | 2024-12-19T07:59:09Z |
| format | Article |
| id | doaj.art-b0133282f03d4379a392297eb16e2419 |
| institution | Directory Open Access Journal |
| issn | 1179-5514 |
| language | English |
| last_indexed | 2024-12-19T07:59:09Z |
| publishDate | 2015-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Endocrinology and Diabetes |
| spelling | doaj.art-b0133282f03d4379a392297eb16e24192022-12-21T20:29:55ZengSAGE PublishingClinical Medicine Insights: Endocrinology and Diabetes1179-55142015-01-01810.4137/CMED.S31526Canagliflozin Treatment in Patients with Type 2 Diabetes MellitusCurtis Triplitt0Susan Cornell1Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.Midwestern University, Chicago College of Pharmacy, Chicago, IL, USA.Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated with a low risk of hypoglycemia when used either as monotherapy or with other agents not typically associated with increased risk of hypoglycemia. Collaborative, multidisciplinary teams are best suited to provide care to patients with diabetes, and clinical pharmacists can enhance the care provided by these teams. This review aims to provide insight into the mode of action, pharmacology, potential drug–drug interactions, clinical benefits, and safety considerations associated with use of the SGLT2 inhibitor canagliflozin in patients with T2DM and to provide information to enhance clinical pharmacists' understanding of canagliflozin.https://doi.org/10.4137/CMED.S31526 |
| spellingShingle | Curtis Triplitt Susan Cornell Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Clinical Medicine Insights: Endocrinology and Diabetes |
| title | Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus |
| title_full | Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus |
| title_fullStr | Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus |
| title_short | Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus |
| title_sort | canagliflozin treatment in patients with type 2 diabetes mellitus |
| url | https://doi.org/10.4137/CMED.S31526 |
| work_keys_str_mv | AT curtistriplitt canagliflozintreatmentinpatientswithtype2diabetesmellitus AT susancornell canagliflozintreatmentinpatientswithtype2diabetesmellitus |